Full Breakdown
Pfizer and Merck Report Q4 2025 Earnings Amid Patent Challenges
2/4/2026, 2:39:57 PM
Pfizer's Financial Performance and Strategic Moves
Pfizer Inc. reported its fourth-quarter 2025 earnings on February 3, 2026, revealing adjusted earnings per share of $0.66, surpassing analysts' expectations of $0.57. The company generated revenue of $17.56 billion, slightly above the anticipated $16.95 billion, although this represented a 1% decline year-over-year, primarily due to reduced demand for its COVID-19 vaccine and antiviral treatment, Paxlovid. Pfizer also recorded a net loss of $1.65 billion for the quarter, contrasting with a net income of $410 million during the same period in 2024.
Looking ahead, Pfizer has reaffirmed its guidance for 2026, projecting adjusted earnings per share between $2.80 and $3.00, and revenue between $59.5 billion and $62.5 billion. This forecast reflects anticipated declines in COVID-19 product sales, expected to drop by approximately $1.5 billion to $5 billion. Additionally, Pfizer is focusing on long-term growth through its $10 billion acquisition of Metsera, a biotech firm specializing in obesity treatments, and aims to cut costs by about $7.7 billion by the end of 2027.
Merck's Earnings and Future Outlook
Merck & Co. also released its fourth-quarter results on February 3, 2026, reporting adjusted earnings per share of $2.04, exceeding the expected $2.01, and revenue of $16.4 billion, surpassing the forecast of $16.19 billion. This marked a 5% increase in revenue compared to the previous year. However, Merck's outlook for 2026 was more conservative, projecting revenue between $65.5 billion and $67 billion, below analysts' expectations of $67.6 billion. The company anticipates adjusted earnings per share to fall between $5.00 and $5.15, which includes a significant one-time charge of approximately $3.65 per share related to its acquisition of Cidara Therapeutics.
Merck's guidance reflects challenges from upcoming patent expirations for several drugs, including its diabetes medications, Januvia and Janumet, which are expected to face generic competition. The company is also preparing for the expiration of Keytruda's patent in 2028, which could significantly impact future revenue.
Criticism and Market Reactions
Despite the positive quarterly results, both Pfizer and Merck faced scrutiny from investors. Pfizer's shares slipped following its earnings report, attributed to a cautious profit forecast. Analysts have expressed concerns regarding Pfizer's ability to generate substantial returns from its recent acquisitions and product developments. Similarly, Merck's stock experienced a decline in premarket trading, reflecting investor apprehension about the company's ability to maintain growth amid patent challenges.
Official Statements
Pfizer's management emphasized the importance of its recent investments, stating, "We are in a transition period, focusing on long-term growth while managing current challenges." Merck's CEO, Robert M. Davis, noted, "We’re delivering revenue growth while investing for the future," highlighting the company's commitment to innovation despite near-term obstacles.
Verbatim Quotes
- “We’re delivering revenue growth while investing for the future,” — Robert M. Davis, CEO of Merck
Conclusion
Both Pfizer and Merck are navigating a complex landscape characterized by declining sales from COVID-19 products and impending patent expirations. Their recent earnings reports reflect a mix of short-term challenges and long-term strategic investments aimed at sustaining growth in the competitive pharmaceutical market.
